Kenneth Brayman headshot
KB

Kenneth L. Brayman

Professor
Unit: School of Medicine
Department: Department of Surgery
Office location and address
Transplant Center
101 Hospital Dr
Charlottesville, Virginia 22903
Education
University of Pennsylvania School of Medicine, 1981, MD
Biography

Kenneth L. Brayman, MD, PhD, FACS, is the director of UVA's kidney, pancreas and islet transplant programs and the director of the Center for Cellular Therapy and Biologic Therapeutics. He's also the Nabi Professor of Transplantation.

Dr. Brayman received his medical and doctorate degrees from the University of Pennsylvania School of Medicine. He completed his internship and residency in general surgery at the Hospital of the University of Pennsylvania and fellowships in transplantation surgery and surgical endoscopy at the University of Minnesota Hospital. 

He is board certified by the American Board of Surgery and the National Board of Medical Examiners. He serves on numerous committees and is a member of professional and scientific societies including American Association of Kidney Patients, American Pancreatic Association and American Society of Transplant Physicians. Dr. Brayman is also a founding member of the International Pancreas and Islet Transplant Association. He is widely published in scientific and professional journals on topics related to his research and clinical experience.

Dr. Brayman has over twenty years of experience as a principal investigator in basic and translational research and clinical trials. His research interests include transplant immunosuppression, chronic allograft nephropathy, solid organ transplantation in patients with HIV, islet cell transplantation, transplantation tolerance, gene therapy and xenotransplantation. He was responsible for developing and establishing the Islet Isolation GMP Facility at UVA, and he has overseen the allo- and auto-transplantation of islets in more than 20 recipients. The Islet Transplant Program, headed by Dr. Brayman, uses an FDA-approved Human Islet Isolation class 10,000 GMP Facility at UVA for the isolation of clinical-grade pancreatic islets for transplants and currently participates with the NIH-sponsored Collaborative Islet Transplant Registry (CITR).

MD-SURG Ph. 2A Randomized Open-Label Active Control Multi-Center Study to Assess Efficacy & Safety of Bleselumab in Preventing Recurrence of Focal Segmental Glomerulosclerosis in de novo Kidney Transplant Recipients
Source: Astellas Pharma Global Development, Inc.
December 14, 2016 – September 18, 2024
Brayman Consulting Agreement with eGenesis
Source: EGENESIS, INC.
March 30, 2021 – March 30, 2022
MD-SURG Protocol #0113-CL-2001 A Phase 2 Trial to Evaluate the Efficacy and Safety of Vaccine AP0113 in Cytomegaiovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor
Source: Astellas Pharma Global Development, Inc.
June 30, 2014 – December 31, 2021
mDOT for Transplant
Source: Emocha Mobile Health Inc.
September 01, 2020 – August 31, 2021
MD-SURG Restoring Immune Homeostasis with IgM Immunothereapy
Source: American Diabetes Association
January 01, 2017 – June 30, 2021
MD-SURG Astellas Brayman ASKP1240
Source: Astellas Pharma Global Development, Inc.
January 23, 2013 – December 31, 2017
Collaborative Islet Transplant Registry
Source: The EMMES Corporation
September 22, 2012 – August 31, 2017
MD-SURG A Phase III Study to Evaluate the Safety & Efficacy of Fibrin Sealant Grifols(FS Grifols) as an Adjunct to Hemostasis During Parenchymous Tissue Open Surgeries
Source: Grifols Inc.
August 07, 2013 – August 07, 2017
MD-SURG Hepatocyte Tissue Bank and Data Repository
Source: Triangle Research Labs, LLC
June 01, 2012 – June 30, 2016
MD-SURG Naturally-Occurring Immunoglobulin M (IgM) Antibodies to Prevent Autoimmune Diabetes
Source: IgM Immunotherapy, LLC
June 03, 2013 – September 30, 2015
Astellas Brayman Diann
Source: Astellas Pharma Global Development, Inc.
February 16, 2012 – February 16, 2015
I5NP for DGF in Kidney Transplant
Source: Quark Pharmaceuticals, Inc.
December 13, 2010 – March 31, 2014
Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy
Source: Wyeth-Ayerst Pharmaceuticals, Inc.
January 08, 2010 – December 31, 2013
Safety and Efficacy of Concentration-Controlled Everolimus
Source: Novartis Pharmaceuticals Corporation
September 30, 2009 – May 11, 2013
CELL 9999: Non-Topical Research
Credits: 1–12
For doctoral dissertation, taken under the supervision of a dissertation director.